Se connecter Inscription gratuite

Last updated: 20 June 2023 at 4:41pm EST

Michael Dougherty Net Worth




The estimated Net Worth of Michael R Dougherty is at least $348 millier dollars as of 1 June 2021. Mr. Dougherty owns over 85,000 units of Marinus Pharmaceuticals Inc stock worth over $185,682 and over the last 10 years he sold MRNS stock worth over $0. In addition, he makes $162,700 as Independent Director at Marinus Pharmaceuticals Inc.

Mr. Dougherty MRNS stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 85,000 units of MRNS stock worth $101,150 on 1 June 2021.

The largest trade he's ever made was buying 85,000 units of Marinus Pharmaceuticals Inc stock on 1 June 2021 worth over $101,150. On average, Michael trades about 2,244 units every 58 days since 2014. As of 1 June 2021 he still owns at least 133,584 units of Marinus Pharmaceuticals Inc stock.

You can see the complete history of Mr. Dougherty stock trades at the bottom of the page.





Michael Dougherty biography

Michael R. Dougherty serves as Independent Director of the Company. Mr. Dougherty has over 35 years of experience in the biopharmaceutical industry, most recently serving as executive chairman of Celator Pharmaceuticals, Inc. (Celator) (sold to Jazz Pharmaceuticals plc) from August 2015 to July 2016, where he also served as a director from July 2013 to July 2016. Mr. Dougherty has continued to serve on the boards of directors of life science companies since leaving Celator in July 2016. Mr. Dougherty previously served in a variety of senior positions in the industry, including as chief executive officer at Kalidex Pharmaceuticals, Inc., president and chief executive officer at Adolor Corporation; president and chief operating officer at Genomics Collaborative, Inc.; president and chief executive officer at Genaera Corporation, and chief financial officer at Centocor, Inc. Mr. Dougherty is currently on the board of directors at Trevena, Inc. (Nasdaq: TRVN) and Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), and previously served on the boards of directors of Foundation Medicine, Inc., Aviragen Therapeutics, Inc. (now known as Vaxart, Inc.) (Nasdaq: VXRT), Cempra, Inc. (now known as Melinta Therapeutics, Inc.) (Nasdaq: MLNT), and Viropharma Incorporated. Mr. Dougherty received a bachelor’s degree in Accounting from Villanova University.

What is the salary of Michael Dougherty?

As the Independent Director of Marinus Pharmaceuticals Inc, the total compensation of Michael Dougherty at Marinus Pharmaceuticals Inc is $162,700. There are 9 executives at Marinus Pharmaceuticals Inc getting paid more, with Scott Braunstein having the highest compensation of $2,245,680.



How old is Michael Dougherty?

Michael Dougherty is 62, he's been the Independent Director of Marinus Pharmaceuticals Inc since 2017. There are 5 older and 9 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..

What's Michael Dougherty's mailing address?

Michael's mailing address filed with the SEC is C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK, PA, 19087.

Insiders trading at Marinus Pharmaceuticals Inc

Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... et Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.



What does Marinus Pharmaceuticals Inc do?

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides



What does Marinus Pharmaceuticals Inc's logo look like?

Marinus Pharmaceuticals Inc logo

Complete history of Mr. Dougherty stock trades at Idera Pharmaceuticals, Marinus Pharmaceuticals Inc et Trevena Inc

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
1 Jun 2021 IDRA Idera Pharmaceuticals, Inc. Michael R Dougherty
Acheter 85,000 $1.19 $101,150
1 Jun 2021
133,584 ↗
10 Dec 2014 TRVN Trevena Inc Michael R Dougherty
Directeur
 Acheter 7,000 $4.00 $28,000
10 Dec 2014
7,000 ↗


Marinus Pharmaceuticals Inc executives and stock owners

Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: